Previous 10 | Next 10 |
FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN) Study will enroll and genetically test over 3,000 FTD patients at multiple sites in seven countries There are cur...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, and Twist Bioscience Cor...
Collaborative research utilized insights gained from CENTOGENE’s rare disease-centric Bio/Databank to help analyze data of more than 20,000 families Enabled testing of successful targeted therapeutic approach that restored embryonic development in preclinical models of birth de...
The following slide deck was published by Centogene N.V. in conjunction with this event. For further details see: Centogene (CNTG) Presents At Global Healthcare Virtual Conference 2021 - Slideshow
Image source: The Motley Fool. Centogene N.V. (NASDAQ: CNTG) Q2 2021 Earnings Call Sep 07, 2021 , 8:00 a.m. ET Lennart Streibel Continue reading For further details see: Centogene N.V. (CNTG) Q2 2021 Earnings Call Transcript
Centogene N.V. (CNTG) Q1 2021 Earnings Conference Call September 7, 2021 8:00 AM ET Company Participants Lennart Streibel - Investor Relations Andrin Oswald - Chief Executive Officer René Just - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Catherine Sch...
The following slide deck was published by Centogene N.V. in conjunction with their 2021 Q2 earnings call. For further details see: Centogene N.V. 2021 Q2 - Results - Earnings Call Presentation
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced financial results for the second quarte...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its financial result...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the appointment of Dr. Patrice P. Den...
News, Short Squeeze, Breakout and More Instantly...
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answer...
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company ...
CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...